Novo Nordisk Lifts Outlook Following Q1 Earnings Beat
Novo Nordisk reported a Q1 adjusted operating profit of 32.86 billion crowns, beating forecasts. It raised its outlook as it relies on Wegovy to drive growth.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B reported Q1 adjusted operating profit of 32.86 billion Danish crowns, beating analyst forecasts of 28.74 billion crowns. The Denmark drugmaker narrowed its 2026 sales and profit decline outlook to a range of 4% to 12%. Investors are weighing whether new oral weight-loss pills can offset pricing pressure and competition in the United States.
